Citations

Clear

3942 citation(s) found for "To, Van".

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, Milind , Lowery, Maeve A. , Shroff, Rachna T. , Weiss, Karl Heinz , Springfeld, Christoph , Ramanathan, Ramesh K., Sadeghi, Saeed , Macarulla, Teresa , Kelley, Robin Kate , Borbath, Ivan , Choo, Su Pin , Oh, Do‐Youn , Reungwetwattana, Thanyanan , Yeh, Kun‐Huei , Ciombor, Kristen K. , Patel, Anuradha , Porter, Dale, Isaacs, Randi , Zhu, Andrew X. , Bekaii‐Saab, Tanios , Lowery, Maeve, Goyal, Lipika , El-Khoueiry, Anthony, Chen, Li‐Tzong , van Cutsem, Eric, Ciombor, Kristen, Sen, Suman, Abou-Alfa, Ghassan K, Bekaii-Saab, Tanios S , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Philip, Philip A. , Cutsem, Eric Van , Finn, Richard S. , Sen, Suman , Abou‐Alfa, Ghassan K. , Macarulla, Teresa

Mayo Clinic

Journal of Clinical Oncology | November 28, 2017 | Volume: 36 | Issue: 3 | Pages: 276-282

10.1200/jco.2017.75.5009 | PMID 29182496 Get It

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. Patients received BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles). The primary end point was investigator-assessed overall response rate. Results Sixty-one patients (35 women; median age, 57 years) with FGFR2 fusion (n = 48), mutation (n = 8), or amplification (n = 3) participated. At the prespecified data cutoff (June 30, 2016), 50 patients had discontinued treatment. All responsive tumors contained FGFR2 fusions. The overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression-free survival was 5.8 months (95% CI, 4.3 to 7.6 months). Adverse events included hyperphosphatemia (72.1% all grade), fatigue (36.1%), stomatitis (29.5%), and alopecia (26.2%). Grade 3 or 4 treatment-related adverse events occurred in 25 patients (41%) and included hyperphosphatemia (16.4%), stomatitis (6.6%), and palmar-plantar erythrodysesthesia (4.9%). Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. This promising antitumor activity supports continued development of BGJ398 in this highly selected patient population.
Modern Fixed Imaging Systems Reduce Radiation Exposure to Patients and Providers
Stangenberg, Lars , Shuja, Fahad , Bom, I.M.J. van der , Alfen, Martine H. G. van, Hamdan, Allen D., Wyers, Mark C. , Guzman, Raul J. , Schermerhorn, Marc L. , Alfen, Martine van

Mayo Clinic

Vascular and Endovascular Surgery | November 21, 2017 | Volume: 52 | Issue: 1 | Pages: 52-58

10.1177/1538574417742211 | PMID 29162024 Get It

High-definition fluoroscopic imaging is required to perform endovascular procedures safely and precisely, especially in complex cases, resulting in longer procedures and increased radiation exposure. This is of importance for training institutions as trainees, even with sound instruction in as low as reasonably achievable (ALARA) principles, tend to have high radiation exposures. Recently, there was an upgrade in the imaging system allowing for comparison of radiation exposure to patients and providers. We performed an analysis of consecutive endovascular aneurysm repair (EVAR) and superficial femoral artery (SFA) interventions in the years 2013 to 2014. We recorded body mass index (BMI) and fluoroscopy time (FT) and subsequently matched 1:1 based on BMI, FT, or both. We determined radiation dose using air kerma (AK) and also recorded individual surgeons’ badge readings. Allura Xper FD20 was upgraded to AlluraClarity with ClarityIQ. We identified a total of 77 EVARs (52 pre and 25 post) and 134 SFA interventions (99 pre and 35 post). Unmatched results for EVAR were BMI pre 26.2 versus post 25.8 (kg/m 2 , P = .325), FT 28.1 versus 21.2 (minutes, P = .051), and AK 1178.5 versus 581 (mGy, P < .001), respectively. After matching, there was a 53.2% reduction in AK (846.1 vs 395.9 mGy; P = .004) for EVAR. Unmatched results for SFA interventions were BMI pre 28.1 versus post 26.6 ( P = .327), FT 18.7 versus 16.2 ( P = .282), and AK 285.6 versus 106.0 ( P < .001), respectively. After matching, there was a 57.0% reduction in AK (305.0 vs 131.3, P < .001). The total deep dose equivalent from surgeons’ badge readings decreased from 39.5 to 17 mrem ( P = .029). Aortic and peripheral endovascular interventions can be performed with reduced radiation exposure to patients and providers, employing modern fixed imaging systems with advanced dose reduction technology. This is of particular importance in the light of the increasing volume and complexity of endovascular and hybrid procedures as well as the prospect of decades of radiation exposure during training and practice.
Co‐occurrence of a novel PDGFRB variant and likely pathogenic variant in CASR
DeMeo, Natasha N. , Burgess, Jeremy D. , Blackburn, Patrick R. , Gass, Jennifer , Richter, John E. , Atwal, Herjot, Gerpen, Jay A. van, Atwal, Paldeep S. , Gass, Jennifer M , Richter, John, Atwal, Herjot K, Van Gerpen, Jay A, Atwal, Paldeep S

Mayo Clinic

Clinical Case Reports | November 20, 2017 | Volume: 6 | Issue: 1 | Pages: 8-13

10.1002/ccr3.1265 | PMID 29375828 Get It

Key Clinical Message This case report describes an individual with brain calcifications, cognitive decline, motor dysfunction, and hypocalcaemia. Exome sequencing revealed a previously reported variant in the CASR gene and a variant of uncertain significance in PDGFRB . The clinical phenotype is likely explained by the CASR variant, but we discuss how the PDGFRB variant could also participate in the phenotype.
Development of an in vivo mouse model of discogenic low back pain
Shi, Changgui , Das, Vaskar, Li, Xin , Kc, Ranjan , Qiu, Sujun , O‐Sullivan, InSug , Ripper, Richard, Kroin, Jeffrey S., Mwale, Fackson , Wallace, Atiyayein A., Zhu, Bingqian , Wijnen, André J. van , Ji, Ming-liang , Lü, Jun , Votta‐Velis, Gina , Yuan, Wen, Im, Hee‐Jeong , van Wijnen, Andre J , Zhao, Lan , Yuan, Wen

Mayo Clinic

Journal of Cellular Physiology | November 18, 2017 | Volume: 233 | Issue: 10 | Pages: 6589-6602

10.1002/jcp.26280 | PMID 29150945 Get It

Discogenic low back pain (DLBP) is extremely common and costly. Effective treatments are lacking due to DLBP's unknown pathogenesis. Currently, there are no in vivo mouse models of DLBP, which restricts research in this field. The aim of this study was to establish a reliable DLBP model in mouse that captures the pathological changes in the disc and allows longitudinal pain testing. The model was generated by puncturing the mouse lumbar discs (L4/5, L5/6, and L6/S1) and removing the nucleus pulposus using a microscalpel under the microscope. Histology, molecular pathways, and pain‐related behaviors were examined. Over 12 weeks post‐surgery, animals displayed the mechanical, heat, and cold hyperalgesia along with decreased burrowing and rearing. Histology showed progressive disc degeneration with loss of disc height, nucleus pulposus reduction, proteoglycan depletion, and annular fibrotic disorganization. Immunohistochemistry revealed a substantial increase in inflammatory mediators at 2 and 4 weeks. Nerve growth factor was upregulated from 2 weeks to the end of the experiment. Nerve fiber ingrowth was induced in the injured discs after 4 weeks. Disc‐puncture also produced an upregulation of neuropeptides in dorsal root ganglia neurons and an activation of glial cells in the spinal cord dorsal horn. These findings indicate that the cellular and structural changes in discs, as well as peripheral and central nervous system plasticity, paralleled persistent, and robust behavioral pain responses. Therefore, this mouse DLBP model could be used to investigate mechanisms underlying discogenic pain, thereby facilitating effective drug screening and development of treatments for DLBP.
Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Purnell, Jonathan Q. , Braffett, Barbara H. , Zinman, Bernard, Gubitosi‐Klug, Rose , Sivitz, William, Bantle, John P., Ziegler, Georgia, Cleary, Patricia A., Brunzell, John D. , Nathan, D.M., Zinman, B., Crofford, O., Genuth, S., Brown-Friday, J., Crandall, J., Engel, S., Martinez, H., Phillips, M., Reid, M., Shamoon, H., Sheindlin, J., Gubitosi-Klug, R., Mayer, L., Pendegast, S., Zegarra, H., Miller, D., Singerman, L., Smith-Brewer, S., Novak, M., Quin, J., Genuth, Saul, Palmert, M., Brown, E., McConnell, J., Pugsley, P., Crawford, P., Dahms, W., Gregory, N.S., Lackaye, M.E., Kiss, S., Chan, R., Orlin, A., Rubin, M., Brillon, D., Reppucci, V., Lee, T., Heinemann, M., Chang, S., Levy, B., Jovanovic, L., Richardson, M., Bosco, B., Dwoskin, A., Hanna, R., Barron, S., Campbell, R., Bhan, A., Krüger, D., Jones, J.K., Edwards, P.A., Bhan, A., Carey, J.D., Angus, E., Thomas, A., Galprin, A., McLellan, M., Whitehouse, F., Bergenstal, R., Johnson, M., Gunyou, K., Thomas, L., Laechelt, J., Hollander, P., Spencer, M., Kendall, D., Cuddihy, R., Callahan, P., List, S., Gott, J., Rude, N., Olson, B., Franz, M., Castle, G., Birk, R., Nelson, J., Freking, D., Gill, L., Mestrezat, W., Etzwiler, D., Morgan, K., Aiello, L.P., Golden, E., Arrigg, P., Asuquo, V., Beaser, R., Bestourous, L., Cavallerano, J., Cavicchi, R., Ganda, O., Hamdy, O., Kirby, R., Murtha, T., Schlossman, D., Shah, S., Sharuk, G., Silver, P., Silver, P., Stockman, M., Sun, J., Weimann, E., Wolpert, H., Aiello, L. M., Jacobson, A., Rand, L., Rosenzwieg, J., Nathan, D.M., Larkin, M.E., Christofi, M., Folino, K., Godine, J., Lou, P., Stevens, C., Anderson, E., Bode, H., Brink, S., Cornish, C., Cros, D., Delahanty, L., deManbey, A., Haggan, C., Lynch, J., McKitrick, C., Norman, D., Moore, D., Ong, M., Taylor, C., Zimbler, D., Crowell, S., Fritz, S., Hansen, K., Gauthier‐Kelly, C., Service, F. J., Ziegler, G., Barkmeier, A., Schmidt, L., French, B., Woodwick, R., Rizza, R., Schwenk, W. F., Haymond, M., Pach, J., Mortenson, J., Zimmerman, B., Lucas, A., Colligan, R., Luttrell, L., Lopes-Virella, M., Caulder, S., Pittman, C., Patel, N., Lee, K., Nutaitis, M., Fernandes, J., Hermayer, K., Kwon, S., Blevins, A., Parker, J., Colwell, J., Lee, D., Soule, J., Lindsey, P., Bracey, M., Farr, A., Elsing, S., Thompson, T., Selby, J., Lyons, T., Yacoub-Wasef, S., Szpiech, M., Wood, D., Mayfield, R., Molitch, M., Adelman, D., Colson, S., Jampol, L., Lyon, A., Gill, M., Strugula, Z., Kaminski, L., MIRZA, R., Simjanoski, E., Ryan, D., Johnson, C., Wallia, A., Ajroud-Driss, S., Astelford, P., Leloudes, N., Degillio, A., Schaefer, B., Mudaliar, S., Lorenzi, G., Goldbaum, M., Jones, K., Prince, M., Swenson, M., Grant, I., Reed, R., Lyon, R., Kolterman, O., Giotta, M, Clark, T., Friedenberg, G., Sivitz, W.I., Vittetoe, B., Kramer, J., Bayless, M., Zeitler, R., Schrott, H., Olson, N., Snetselaar, L., Hoffman, R., MacIndoe, J., Weingeist, T., Fountain, C., Miller, R., Johnsonbaugh, S., Patronas, M., Carney, M., Mendley, S., Salemi, P., Liss, R., Hebdon, M., Counts, D., Donner, T., Gordon, J., Hemady, R., Kowarski, A., Ostrowski, D., Steidl, S., Jones, B., Herman, W.H., Martin, C.L., Pop-Busui, R., Greene, D. A., Stevens, M.J., Burkhart, N., Sandford, T, Floyd, J., Bantle, J., Flaherty, N., Terry, J., Koozekanani, D., Montezuma, S., Wimmergren, N., Rogness, B., Mech, M., Strand, T., Olson, J., McKenzie, L., Kwong, C., Goetz, F., Warhol, R., Hainsworth, D., Goldstein, D., Hitt, S., Giangiacomo, J., Schade, D.S., Canady, J.L., Burge, M. R., Das, A., Avery, R.B., Ketai, L.H., Chapin, J.E., Schluter, M.L, Rich, J., Johannes, C., Hornbeck, D., Schutta, M., Bourne, P.A., Brucker, A., Braunstein, S., Schwartz, S., Maschak-Carey, B. J., Baker, L., Orchard, T., Cimino, L., Songer, T., Doft, B., Olson, S., Becker, D., Rubinstein, D., Bergren, R.L., Fruit, J., Hyre, R., Palmer, C., Silvers, N., Lobes, L., Rath, P. Paczan, Conrad, P. W., Yalamanchi, S., Wesche, J., Bratkowksi, M., Arslanian, S., Rinkoff, J., Warnicki, J., Curtin, D., Steinberg, D., Vagstad, G., Harris, R., Steranchak, L., Arch, J., Kelly, K., Ostrosaka, P., Guiliani, M., Good, M., Williams, T., Olsen, K., Campbell, A., Shipe, C., Conwit, R., Finegold, D., Zaucha, M., Drash, A., Morrison, A., Malone, J.I., Bernal, M.L., Pavan, P. R., Grove, N., Tanaka, E.A., McMillan, D., Vaccaro‐Kish, J., Babbione, L., Solc, H., DeClue, T.J., Dagogo-Jack, S., Wigley, C., Ricks, H., Kitabchi, A., Chaum, E., Murphy, M.B., Moser, S., Meyer, D., Iannacone, A., Yoser, S., Bryer‐Ash, M., Schüßler, S., Lambeth, H., Raskin, P., Strowig, S., Basco, M., Cercone, S., Zinman, B., Barnie, A., Devenyi, R., Mandelcorn, M., Brent, M., Rogers, S., Gordon, A., Bakshi, N., Perkins, B., Tuason, L., Perdikaris, F., Ehrlich, R., Daneman, D., Perlman, K., Ferguson, S., Palmer, J., Fahlstrom, R., Boer, I.H.de, Kinyoun, J., Ottingham, L. Van, Catton, S., Ginsberg, J., McDonald, C., Harth, J., Driscoll, M., Sheidow, T., Mahon, J., Canny, C., Nicolle, D., Colby, P., Dupre, J., Hramiak, I., Rodger, NW, Jenner, M., Smith, T., Brown, W., May, M., Hagan, J. Lipps, Agarwal, A., Adkins, T., Lorenz, R., Feman, S., Survant, L., White, N. H., Levandoski, L., Grand, G., Thomas, M., Joseph, D., Blinder, K., Shah, G., Burgess, D., Boniuk, I., Santiago, J., Tamborlane, W., Gatcomb, P., Stoessel, K., Ramos, P., Fong, K., Ossorio, P., Ahern, J., Meadema-Mayer, L., Beck, C., Farrell, K., Quin, J., Gaston, P., Trail, R., Lachin, J., Backlund, J., Bebu, I., Braffett, B., Diminick, L., Gao, X., Hsu, W., Klumpp, K., Trapani, Victoria R., Trapani, V., Cleary, P., McGee, P., Sun, W. , Villavicencio, S., Anderson, K., Dews, L., Younes, Naji , Rutledge, B., Chan, K., Rosenberg, D. , Petty, B., Determan, A., Kenny, D., Williams, C., Cowie, C., Siebert, C., Steffes, M., Arends, V., Bucksa, J., Nowicki, M., Chavers, B., O’Leary, D., Polák, J. (Jaroslav), Harrington, A., Funk, L., Crow, R., Gloeb, B., Thomas, S., O’Donnell, C., Soliman, EZ, Zhang, Z.M., Li, Y., Campbell, C., Keasler, L., Hensley, S., Hu, J., Barr, M., Taylor, T., Prineas, R., Feldman, E.L., Albers, J.W., Low, P., Sommer, C., Nickander, K., Speigelberg, T., Pfiefer, M., Schumer, M., Moran, M., Farquhar, J., Ryan, C., Sandstrom, D., Geckle, M., Cupelli, E., Thoma, F., Burzuk, B., Woodfill, T., Danis, R., Blodi, B., Lawrence, D., Wabers, H., Gangaputra, S., Neill, S., Burger, M., Dingledine, J., Gama, V., Sussman, R., Davis, M., Hubbard, L., Budoff, M., Darabian, S., Rezaeian, P., Wong, N., Fox, M., Oudiz, R., Kim, L., Detrano, R., Cruickshanks, K., Bainbridg, K., Lima, J., Bluemke, D., Turkbey, E., Geest, R. J. van der, Liu, C., Malayeri, A., Jain, A., Miao, C., Chahal, H., Jarboe, R., Nathan, D.M., Monnier, V., Sell, D., Strauch, C., Hazen, S., Pratt, A., Tang, W., Brunzell, J., Purnell, J., Purnell, J., Natarajan, R., Miao, F., Zhang, L., Chen, Z., Paterson, A., Boright, A., Bull, S., Sun, L., Scherer, S., Lyons, T.J., Jenkins, A., Klein, R., Virella, G., Jaffa, A., Carter, R., Stoner, J., Garvey, W.T., Lackland, D., Brabham, M., McGee, D., Zheng, D., Mayfield, R. K., Maynard, J., Wessells, H., Sarma, A., Dunn, R., Holt, S., Hotaling, J., Kim, C., Clemens, Q., McVary, Kevin T. , Cuddihy, Robert , Paterson, Andrew D. , Gubitosi-Klug, Rose A , Paterson, Andrew , Zinman, Bernard , Sivitz, William I. , Ziegler, G., Nathan, D.M., Engel, Samuel S. , Reid, M., Genuth, Saul, McConnell, J., Campbell, R., Carey, J.D., Dd, Etzwiler, Cavallerano, Jerry D. , Larkin, M.E., DeManbey, Andrea, Ajroud-Driss, S., Mudaliar, S., Herman, W.H., Pop-Busui, R., Mech, Michael, Schade, D.S., Schwartz, S., Becker, Dj., Arch, J., Shipe, C., Drash, A L, Pavan, P R , DeClue, Terry J., Raskin, P., Rogers, S., Boer, I.H. de, Dupre, J, Tamborlane, W., Gatcomb, P., Bebu, I., Cleary, P., McGee, P., Steffes, M., Arends, V., Bm, Chavers, Polak, J., Feldman, E. L., Nickander, K. K., Pfiefer, M., Dittz, Dalton , Virella, Gabriel, Mayfield, R. K., Brown, Jonathan D. , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | November 15, 2017 | Volume: 40 | Issue: 12 | Pages: 1756-1762

10.2337/dc16-2523 | PMID 29138273 Get It

OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence of cardiovascular disease (CVD) events compared with conventional treatment (CONV), but it also results in more weight gain. Our objective was to examine whether excessive weight gain from INT of type 1 diabetes is independently associated with subsequent CVD events. RESEARCH DESIGN AND METHODS Quartiles (Q) of weight gain in 1,213 participants aged 18 years and older at enrollment in the Diabetes Control and Complications Trial (DCCT) were determined within randomized treatment groups (INT vs. CONV) using change in BMI from baseline to the closeout DCCT visits. Effects of this weight gain on CVD risk factors and outcomes during an additional 20 years of observational follow-up were then determined. RESULTS The Q4 INT group experienced greater proportional weight gain (median change in BMI, 6.08 kg/m2), increases in CVD risk factors, and need for medications for hypertension and lipids compared with the Q1–3 INT and comparable CONV groups. Over a mean of 26 years of follow-up, the numbers of major and total CVD events were not statistically different in Q4 compared with Q1–3 of either the INT or CONV group. By year 14, however, the incident CVD event curve became significantly higher in the Q4 INT group than in the Q1–3 INT groups (P = 0.024) and was similar to that for the CONV group. CONCLUSIONS For the first 13 years after DCCT, INT for type 1 diabetes reduced macrovascular events compared with CONV, even when excessive weight gain occurred. After this, total CVD events significantly increased in the Q4 INT group, becoming equivalent to those in the CONV group. Longer follow-up is needed to determine whether this trend continues and results in more major CVD events.
ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome)
Than, Martin , Pickering, John W. , Dryden, Jeremy M., Lord, Sally J., Aldous, Sally, Allan, Kate , Ardagh, Michael, Bonning, John , Callender, Rosie, Chapman, Laura R.E., Christiansen, J., Cromhout, Andre P.J., Cullen, Louise , Deely, Joanne M., Devlin, Gerard, Ferrier, Katherine, Florkowski, Christopher M , Frampton, Christopher , George, Peter M., Hamilton, Gregory J. , Jaffe, Allan S. , Makower, R M, Matthews, Timothy James , Parsonage, William , Pelt, Niels C van, Poynton, Louise, Richards, Mark , Scott, Anthony, Simmonds, Mark, Smyth, David, Thomas, Oliver P., To, Andrew, Toit, Stephen A. Du, Troughton, Richard W. , Yates, Kim , Lord, Sarah J. , Cullen, Louise , Aitken, Stuart A. , Chapman, Laura , Jaffe, Allan S. , Kerr, Andrew Jensen , Larkin, Gregory Luke , Peacock, William Frank , Peckler, Brad , Toit, Stephen Du , Troughton, Richard W , Lord, Sarah J , Richards, Arthur M , Than, Martin , Pickering, John W

Mayo Clinic

Circulation | November 15, 2017 | Volume: 137 | Issue: 4 | Pages: 354-363

10.1161/circulationaha.117.031984 | PMID 29138293 Get It

Background: Efforts to safely reduce length of stay for emergency department patients with symptoms suggestive of acute coronary syndrome (ACS) have had mixed success. Few system-wide efforts affecting multiple hospital emergency departments have ever been evaluated. We evaluated the effectiveness of a nationwide implementation of clinical pathways for potential ACS in disparate hospitals. Methods: This was a multicenter pragmatic stepped-wedge before-and-after trial in 7 New Zealand acute care hospitals with 31 332 patients investigated for suspected ACS with serial troponin measurements. The implementation was a clinical pathway for the assessment of patients with suspected ACS that included a clinical pathway document in paper or electronic format, structured risk stratification, specified time points for electrocardiographic and serial troponin testing within 3 hours of arrival, and directions for combining risk stratification and electrocardiographic and troponin testing in an accelerated diagnostic protocol. Implementation was monitored for >4 months and compared with usual care over the preceding 6 months. The main outcome measure was the odds of discharge within 6 hours of presentation Results: There were 11 529 participants in the preimplementation phase (range, 284–3465) and 19 803 in the postimplementation phase (range, 395–5039). Overall, the mean 6-hour discharge rate increased from 8.3% (range, 2.7%–37.7%) to 18.4% (6.8%–43.8%). The odds of being discharged within 6 hours increased after clinical pathway implementation. The odds ratio was 2.4 (95% confidence interval, 2.3–2.6). In patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% confidence interval, 2.4–3.4). For patients discharged within 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P =0.96). In these patients, no adverse event occurred when clinical pathways were correctly followed. Conclusions: Implementation of clinical pathways for suspected ACS reduced the length of stay and increased the proportions of patients safely discharged within 6 hours. Clinical Trial Registration: URL: https://www.anzctr.org.au/ (Australian and New Zealand Clinical Trials Registry). Unique identifier: ACTRN12617000381381.
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
Bottai, Matteo , Tjärnlund, Anna, Santoni, Giola , Pilkington, Clarissa , Visser, Marianne de, Amato, Anthony A. , Barohn, Richard J., Liang, Matthew H. , Singh, Jasvinder A. , Arnardottir, Snjólaug, Chinoy, Hector , Dankó, Katalin , Dimachkie, Mazen M. , Torre, Ignacio García‐De La , Gordon, Patrick , Hayashi, Taichi, Katz, James D. , Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca , Olesinka, Marzena, Reed, Ann M. , Rutkowska‐Sak, Lidia , Sanner, Helga , Selva-O’Callaghan, Albert , Vencovský, Jiří , Ytterberg, Steven R. , Miller, Frederick W. , Rider, Lisa G. , Engelen, Baziel G.M. van , Huber, Adam M. , Mohammed, Reem , Singh, Jasvinder A , Vencovsky, Jiri , Mohammed, Reem W , Chinoy, Hector , Selva O'Callaghan, Albert , Werth, Victoria P. , Visser, Marianne de, Alfredsson, Lars , Aggarwal, Rohit , Cooper, Robert G. , Feldman, Brian Michael , Li, Yuhui , Oddis, Chester V. , Song, Yeong Wook , Lundberg, Ingrid E. , García-De La Torre, Ignacio , Dimachkie, Mazen M

Mayo Clinic

RMD Open | November 14, 2017 | Volume: 3 | Issue: 2 | Pages: e000507

10.1136/rmdopen-2017-000507 | PMID 29177080 Get It

Objective To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) and their major subgroups. Methods An international, multidisciplinary group of myositis experts produced a set of 93 potentially relevant variables to be tested for inclusion in the criteria. Rheumatology, dermatology, neurology and paediatric clinics worldwide collected data on 976 IIM cases (74% adults, 26% children) and 624 non-IIM comparator cases with mimicking conditions (82% adults, 18% children). The participating clinicians classified each case as IIM or non-IIM. Generally, the classification of any given patient was based on few variables, leaving remaining variables unmeasured. We investigated the strength of the association between all variables and between these and the disease status as determined by the physician. We considered three approaches: (1) a probability-score approach, (2) a sum-of-items approach criteria and (3) a classification-tree approach. Results The approaches yielded several candidate models that were scrutinised with respect to statistical performance and clinical relevance. The probability-score approach showed superior statistical performance and clinical practicability and was therefore preferred over the others. We developed a classification tree for subclassification of patients with IIM. A calculator for electronic devices, such as computers and smartphones, facilitates the use of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria. Conclusions The new EULAR/ACR classification criteria provide a patient’s probability of having IIM for use in clinical and research settings. The probability is based on a score obtained by summing the weights associated with a set of criteria items.
Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131 I Therapy for Differentiated Thyroid Cancer
Gomes-Lima, Cristiane , Wu, Di , Kharazi, Pejman, Khojekar, Gauri J., Ringel, Matthew D. , Vetter, Richard J., Bloom, Gary , Burman, Kenneth D. , Wartofsky, Leonard , Nostrand, Douglas Van , Ringel, Matthew D

Mayo Clinic

Thyroid | November 14, 2017 | Volume: 27 | Issue: 12 | Pages: 1558-1565

10.1089/thy.2017.0124 | PMID 29132255 Get It